Paolo F. Caimi

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +11

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 397 citations

Loncastuximab Tesirine, Lymphoid Neoplasia, Hematological Malignancy +6

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Petros Grivas, Ali Raza Khaki, Trisha M. Wise‐Draper et al. · Annals of Oncology · 2021 · 321 citations · Full text

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson et al. · The Lancet Haematology · 2018 · 226 citations

Hematological Malignancy, Lymphoid Neoplasia, Single-arm Phase 2 +9

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

Keith T. Flaherty, Robert J. Gray, Alice P. Chen et al. · JNCI Journal of the National Cancer Institute · 2020 · 221 citations · Full text